Business
Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs
Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs\n\n\n\n\n\nCannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs\nPR Newswire\nTEL-AVIV, Israel, September 6, 2017\n\n\n\nTEL-AVIV, Israel, September 6, 2017 /PRNewswire/ --\n\nCannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an extensive provisional patent application with the US Patent & Trademark Office (USPTO) on a new Method for Sensitivity Tests of Cannabinoids on Patient-Derived Tumor Biopsies and CTCs.\n\n     (Logo: http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )\n     (Photo: http://mma.prnewswire.com/media/552480/Cannabics_Pharmaceuticals.jpg )\n\n\nThe method, developed by Cannabics Pharmaceuticals, expands the company's proprietary technology of personalization of cannabinoid medicine. The current invention pertains to a combined method and system for assessing the sensitivity of a variety of cannabinoid- based treatment modalities on patient-derived primary tumor biopsies as well as blood circulating tumor cells (CTC). This recent patent filing  is a strong message and a vigorous reflection of the company's target: Cannabics methods and products will enable exquisitely accurate medical cannabis solutions to be applied quite soon into mainstream medical practice.\n\nDr. Moran Grinberg, Cannabics Pharmaceuticals VP of R&D said \"There is a need for a more personalized approach toward drug development and diagnosis that takes into account the diversity of cancer patients, as well as the complex milieu of tumor cells within a single patient. This approach is faced with numerous challenges, including tumor heterogeneity and tumor mutation rates along with insufficient tumor samples available\".\n\nAbout Cannabics Pharmaceuticals Inc. \nCannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cann...